Day One Biopharmaceuticals Inc   (DAWN)
Other Ticker:  
Price: $16.6400 $1.26 8.192%
Day's High: $17.39 Week Perf: 12.05 %
Day's Low: $ 15.11 30 Day Perf: 13.43 %
Volume (M): 6,705 52 Wk High: $ 17.85
Volume (M$): $ 111,568 52 Wk Avg: $13.40
Open: $15.58 52 Wk Low: $9.67

 Market Capitalization (Millions $) 1,430
 Shares Outstanding (Millions) 86
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -40
 Cash Flow (TTM) (Millions $) 120
 Capital Exp. (TTM) (Millions $) 0

Day One Biopharmaceuticals Inc
Day One Biopharmaceuticals is a privately held, clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The company was founded in 2018 by Jeremy Bender, M.D., Ph.D., a former partner at Deerfield Management, and Josh Resnick, CEO of the oncology company, Outpost Medicine. Day One Biopharmaceuticalse primary focus is on developing precision medicines for patients with cancer and autoimmune disorders. The company received $60 million in funding in a Series A round led by ARCH Venture Partners and includes Pfizer Ventures, Lux Capital, GV, and Alexandria Venture Investments.

One of the main reasons for the company's founding is to bring a more personalized approach to cancer treatment. Day One Biopharmaceuticals concentrates on identifying targets that are highly expressed in specific subtypes of cancer and developing highly selective drugs that zero in on those targets. This is done using its proprietary platform, which combines single-cell sequencing, proteomics, and artificial intelligence (AI) techniques to identify and focus on targets that are present only on cancer cells, leaving healthy cells unharmed.

Another area of focus for Day One Biopharmaceuticals is autoimmune diseases since the platform it uses to identify drug targets could also find targets on cells that are driving autoimmune disorders. The company's pipeline starts with two oncology programs targeting the RAS and Myc cancer pathways, both of which are known for their complexity and elusiveness in therapeutic targeting. Day Onees scientific approach is expected to be highly effective, given the complexity of these developmental pathways. Other programs it is working on target novel metabolic pathways in cancer cells as well as cytokine targets and immune cells for autoimmune disease.

In summary, Day One Biopharmaceuticals is an innovative, privately held clinical-stage biopharmaceutical company with a mission to develop highly selective drugs using its proprietary AI-based platform for cancer and autoimmune diseases. With significant funding from a range of investors, the company is well-positioned to make progress in its pipeline of novel therapies.

   Company Address: 2000 Sierra Point Parkway Brisbane 94005 CA
   Company Phone Number: 484-0899   Stock Exchange / Ticker: NASDAQ DAWN


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Clinical Study

FDA Fast-Tracks Approval for OJEMDA, Day One's Novel Treatment for Leading Childhood Brain Tumor, MARKS Major Leap Forward in Pediatric Oncology

Published Tue, Apr 23 2024 7:56 PM UTC

This latest regulatory green light marks just the latest affirmation of Day One's ongoing commitment to revolutionizing the treatment paradigm in pediatric oncology. With gliomas accounting for nearly half of all central nervous system tumors in children, the approval of OJEMDA is set to herald a new era of hope for pediatric patients and their families grappling with this c...

Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals Inc. Shocks Stock Market with Surprising Third Quarter Results

The stock market has been buzzing with speculation and anticipation as industry observers continue to analyze the third quarter earnings of the Major Pharmaceutical Preparations industry. In their scrutiny, one company that has caught their attention is Day One Biopharmaceuticals Inc.
The latest financial reporting period, covering July to September 2023, saw Day One Biopharmaceuticals Inc report an operating deficit of -$51.438 million. While the company has yet to disclose any top-line figures, investors remain optimistic about the future revenue streams that may emerge in the near future.

Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals Inc Struggles Financially, Reporting Significant Operating Shortfall in Q2 2023

With the release of the second quarter results for Day One Biopharmaceuticals Inc, it is evident that the company is currently experiencing some financial challenges. The Major Pharmaceutical Preparations sector consultants have observed an operating shortfall of $-49.254 million, indicating that the company has not generated any revenue during the April to June 30, 2023 quarter.
This presents a significant contrast to the same period last year, where the operating shortfall was $-36.719 million. However, it is crucial to note that Day One Biopharmaceuticals Inc reported a net deficit of $0.000 million in the second quarter of 2023, compared to a deficit of $-36.530 million in the corresponding period a year ago.



About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com